HLA-G and myeloid sarcoma: Moreover, preliminary results from our laboratory have demonstrated that, MS patients present dimeric sHLA-G form more frequently than control, in particular in MRI inactive MS patients (unpublished data), suggesting that large amounts of biologically active dimeric sHLA-G form could be released in CSF of MS patients, possibly induced by pharmacological treatment (118).